Liquidambaric acid as a non-competitive α-glucosidase inhibitor: multi-level evidence from enzyme kinetics, molecular docking, molecular dynamics simulations, and a Drosophila hyperglycaemic model
Journal of Enzyme Inhibition and Medicinal Chemistry · 31.12.2025 · 40 (1)
DOI: 10.1080/14756366.2025.2497486 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Enzyme Inhibition and Medicinal Chemistry, online erschienen am 29.04.2025. Verfasst von Liwei Jia und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, PR China. Hauptthemen laut MEDLINE: Glycoside Hydrolase Inhibitors, Molecular Docking Simulation, alpha-Glucosidases, Molecular Dynamics Simulation. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Heilongjiang Provincial Natural Science Foundation of China, Science Foundation of Heilongjiang Administration of Traditional Chinese Medicine.
Abstract (Originalsprache)
Liquidambaric acid, a pentacyclic triterpenoid from Liquidambar formosana Hance, was evaluated as a novel α-glucosidase inhibitor for type 2 diabetes mellitus (T2DM) management. Enzyme kinetic assays revealed its potent non-competitive inhibition (IC50 = 0.12 mM). Molecular docking showed stable hydrogen bonding at an allosteric site, altering enzyme conformation, while 100 ns molecular dynamics (MD) simulations confirmed the stability of the protein-ligand complex. In vivo, a Drosophila melanogaster hyperglycaemic model demonstrated significant glucose reduction, confirming its hypoglycaemic potential. ADMET analysis predicted favourable bioavailability and low toxicity, supporting its development as a safe therapeutic agent. These findings integrate enzyme kinetics, molecular modelling, MD simulations, and in vivo validation, highlighting liquidambaric acid's potential as a multifunctional and cost-effective agent for T2DM management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, PR China.
Förderung
- Heilongjiang Provincial Natural Science Foundation of China
- Science Foundation of Heilongjiang Administration of Traditional Chinese Medicine
Zitieren
APA
Jia, L., Liu, Y., Fu, B., Tian, Y., & Meng, X. (2025). Liquidambaric acid as a non-competitive α-glucosidase inhibitor: multi-level evidence from enzyme kinetics, molecular docking, molecular dynamics simulations, and a Drosophila hyperglycaemic model. Journal of Enzyme Inhibition and Medicinal Chemistry, 40(1). https://doi.org/10.1080/14756366.2025.2497486
Vancouver
Jia L, Liu Y, Fu B, Tian Y, Meng X. Liquidambaric acid as a non-competitive α-glucosidase inhibitor: multi-level evidence from enzyme kinetics, molecular docking, molecular dynamics simulations, and a Drosophila hyperglycaemic model. Journal of Enzyme Inhibition and Medicinal Chemistry. 2025;40(1). doi:10.1080/14756366.2025.2497486
BibTeX
@article{Jia2025,
author = {Jia, Liwei and Liu, Yan and Fu, Bo and Tian, Yuan and Meng, Xin},
title = {Liquidambaric acid as a non-competitive α-glucosidase inhibitor: multi-level evidence from enzyme kinetics, molecular docking, molecular dynamics simulations, and a Drosophila hyperglycaemic model},
journal = {Journal of Enzyme Inhibition and Medicinal Chemistry},
year = {2025},
volume = {40},
number = {1},
doi = {10.1080/14756366.2025.2497486}
}
EUVIMED